We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current FPHAF market cap is 227M. The company's latest EPS is EUR -0.4499 and P/E is -2.17.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -13.1M | -16.65M | -21.11M | -27.43M | -28.57M |
| Net Income | -13.26M | -16.95M | -21.19M | -28.73M | -30.94M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 10.21M | 8.37M | 13.18M | 11.27M | 10.22M |
| Total Liabilities | 8.6M | 10.22M | 10.26M | 22.75M | 25.38M |
| Total Equity | 1.61M | -1.85M | 2.92M | -11.48M | -15.16M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -11.52M | -17.48M | -22.22M | -22.99M | -23.81M |
| Investing | -100k | -142k | -473k | -385k | -123k |
| Financing | 14.61M | 14.79M | 25.59M | 23.48M | 23.98M |
| Market Cap | 227M |
| Price to Earnings Ratio | -2.17 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 9.76 |
| Price to Book Ratio | -4.42 |
| Dividend Yield | - |
| Shares Outstanding | 68.79M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Faron Pharmaceuticals Oy (PK) |
| Address |
joukahaisenkatu 6, intelligate turku FIN-20520 |
| Website | https://www.faronpharmaceuticals.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
